Radiopharm Theranostics Ltd has released a press release.
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Story so far
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
- RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
- ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
- Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
- Acceleration of RAD204 Phase 1 dose escalation trial
Later from Radiopharm Theranostics
- Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
- RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
- Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
- Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
- Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics